+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2nd Annual Cell Therapy Bioprocessing Conference (Boston, MA, United States - June 25-26, 2020)

  • ID: 4912212
  • Conference
  • Location: Boston, MA, United States
  • 2 Days
  • Markets and Markets Conferences
  • Conference Dates: June 25-26, 2020
1 of 5

Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. In our conference of 2017, we assessed the specific risks and benefits of the cell culture and cell therapy bio-manufacturing for the cure of these diseases.

There are still factors like manufacturing maze, investment, logistics and regulatory challenges which prevents the cell and gene therapies to be widely used. We are once again putting together a unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges, at our 2nd Annual Cell Therapy Bioprocessing Conference, taking place at Boston-USA on 25th & 26th June 2020.

Key Highlights

  • Bioprocessing of 3D cell culture
  • CHO cell lines bioprocessing
  • Automation of cellular therapies
  • AAV vector production
  • Process development and monitoring of cell-gene therapies
  • Optimization of cell-gene therapies
  • Supply chain and reimbursement issues
  • Regulatory guidelines cell and gene-based medicines

Why Attend

  • Learn the latest advancement and opportunities in the area of manufacturing of cell-gene therapies
  • Gain insights in the area of the automated and most effective manufacturing processes
  • Network with the key professionals addressing the strategies of supply chain and regulatory hurdles
Note: Product cover images may vary from those shown
2 of 5

Day 1: Thursday June 25th

CELL CULTURE TO CELL THERAPY
Self-regulated bioprocessing through bioreactor system for monitored 3D cell culture
09:00 - 09:30
Multi-omics study on CHO cell lines engineering and bioprocessing
09:30 - 10:00
Solution provider presentation
10:00 - 10:30
Morning refreshment and One on One Networking
10:30 - 11:20

CELL THERAPY BIOPROCESSING AND DEVELOPMENT
Next generation engineered T cells for cell therapy
11:20 - 11:50 Jan Joseph Melenhorst, Adjunct Associate Professor, Upenn
Automation of cellular therapies: challenges and solutions
11:50 - 12:20
Solution provider presentation
12:20 - 12:50
Lunch and One on One Networking
12:50 - 13:50
Development of Stem Cell Derived Exosomes for Clinical Applications
13:50 - 14:20 Ian McNiece, Vice President, Aegle Therapeutics
Bioprocessing of recombinant adeno‐associated virus production by fluorescence spectroscopy
14:20 - 14:50
Afternoon refreshment and One on One Networking
14:50 - 15:20

PROCESS MONITORING & QUALITY CONTROL
Process development of antigen-specific T cells
16:10 - 16:40 Patrick J. Hanley, Director of GMP for Immunotherapy, The Children’s Research Institute
Establishing iPSC cell banks derived using reagents and workflows optimized for cell therapy manufacturing
16:40 - 17:10
Glycolysis restriction through fermentation technology to preserve T-cell functions and checkpoint therapy
17:10 - 17:40
Closing remarks by Chairperson
17:40 - 17:45
Drinks reception
17:45 - 18:45
End of Conference
18:45 - 18:45

Day 2: Friday June 26th

Scale up of allogeneic cell therapy manufacturing in single-use bioreactors: Challenges, insights and solutions
09:00 - 09:30
Cell therapy: progress in manufacturing and assessments of potency
09:30 - 10:00
Solution provider presentation
10:00 - 10:30
Morning refreshment and One on One Networking
10:30 - 11:20
Panel Discussion: Autologous vs Allogenic
11:20 - 11:50
Quality control and effective purification methods for cell therapy product lines
11:50 - 12:20
Solution provider presentation
12:20 - 12:50
Lunch and One on One Networking
12:50 - 13:50

LOGISTICS, REGULATORY & INVESTMENT
Building a leading edge supply chain, while maintaining flexibility
13:50 - 14:20 Devyn Smith, Chief Operating Officer, Sigilon Therapeutics
Raw and starting material control for cell-based medicines
14:20 - 14:50
FDA guidelines for regulatory issues involved cell therapy manufacturing
14:50 - 15:20
Closing remarks by Chairperson
15:20 - 15:25
End of Conference
15:25 - 15:25

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Shailendra Singh (Shelly) Shailendra Singh (Shelly),
    Chief Operating Officer ,
    MarketsandMarkets


    Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.
     

  • Tiffany Rau Tiffany Rau,
    Global Leader in Process Development (R &D, CMC), Manufacturing, & Commercialization-, Biotechnology ,
    Vanderbilt University




     

  • Devyn Smith Devyn Smith,
    Chief Operating Officer ,
    Sigilon Therapeutics


    Devyn joined Sigilon Therapeutics in early 2017 as Chief Operating Officer and Head of Strategy. In this role, he has helped build the company to over 100 colleagues. Operational achievements include building out the CMC group and initiating GMP manufacturing of our lead program, building the quality systems and group to oversee the portfolio, keeping the portfolio moving through successful project management and portfolio oversight. In addition, he has led the build out of the corporate strategy, portfolio strategy and other key strategy elements. He joined Pfizer's Medicinal Sciences Division of R&D as Head of Business Operations & Strategy in 2016 overseeing both day to day business operations of the division, as well insuring implementable strategies are developed. Prior to this Devyn was Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D focused on developing and implementing core strategies in Winning by Design in Small Molecules as well as optimizing the ROI on novel technology inventions.
     

  • Jan Joseph Melenhorst Jan Joseph Melenhorst,
    Adjunct Associate Professor ,
    Upenn



    Dr. Jan Joseph (Jos) Melenhorst obtained his PhD at the LUMC (Department of Hematology) on the pathogenesis of Aplastic Anemia. In 1998 he moved to Bethesda, Maryland, where he did his research ‐ first as a postdoc, later as a staff scientist ‐ in the laboratory of Dr. John Barrett at the National Institutes of Health, on the immunobiology of marrow failure syndromes, leukemic disorders, and allogeneic stem cell transplantation. In 2012 he was recruited by Dr. Bruce Levine and Dr. Carl June to the University of Pennsylvania, first as Deputy Director of their clinical manufacturing (cGMP) facility. After a year he was promoted to Director of Product Development & Correlative Sciences. In this role, he was at the cusp of the first ever CAR T cell therapy approved by FDA: Kymriah. Dr. Melenhorst is interested in understanding and improving the anti-tumor efficacy and safety of adoptively transferred chimeric antigen receptor-modified T cells through correlative, mechanistic, and functional genomics approaches.
     

  • Ian McNiece Ian McNiece,
    Vice President ,
    Aegle Therapeutics



    Ian McNiece, PhD is VP of Research and Development at Aegle Therapeutics, which is based in Miami FL. He joined Aegle in 2017 and is responsible for the Manufacturing, Regulatory and Development efforts of the company. Aegle is developing extracellular vesicles (EVs) from MSCs to treat severe dermatological conditions, including burns and epidermolysis bullosa (EB). He received a Ph.D. in physiology in 1986 from the University of Melbourne undertaking his thesis work at the Peter MacCallum Cancer Institute. He was appointed to the position of Director of the Division of Biomedical Sciences Johns Hopkins in Singapore in 2004. At Miami his research focused on the use of stem cells for repair of cardiac tissue including the manufacture of MSCs for clinical trials. His research has focused on aspects of stem cell biology and in particular control of proliferation and differentiation of stem cells by growth factors and stromal cells. Much of his work has studied aspects of stem cells in clinical marrow and stem cell transplantation leading to clinical trials in mobilization and ex vivo expansion.
     

  • Patrick J. Hanley Patrick J. Hanley,
    Director of GMP for Immunotherapy ,
    The Children’s Research Institute


    Dr. Hanley is an assistant research professor of pediatrics and Director of the Cellular Therapy Laboratory at Children’s National Hospital. He oversees processing for standard of care stem cell transplantation as well as the development, manufacture, and testing of novel cell therapies for patients enrolled on clinical trials. Trained as an Immunologist. He has an extensive background and interest in cellular therapy and is passionate about improving regulations for cellular therapy, training the next generation of cell therapists, and facilitating the translation of new therapeutics. Over the past 13 years he has helped to translate more than 20 cell therapy protocols – ranging from mesenchymal stromal cells to cord blood virus-specific T cells and tumor-associated antigen specific T cells – into the clinic. He is on the board of directors of the Foundation for the Accreditation of Cellular Therapy (FACT), is an active inspector, is chair of FACT’s education committee, serves on their accreditation committee and is also on the immune effector cell standards subcommittee. He serves on the editorial boards of the journals Cytotherapy and Molecular Therapy: Methods and Clinical Development. In 2017, along with Drs Catherine Bollard and Russell Cruz, he founded Mana Therapeutics, a biotech company aimed at educating immune cells and eliminating cancer. In his free time he enjoys playing soccer, cooking, and traveling.
     

  • Govindarajan Dhanasekaran Mr Govindarajan Dhanasekaran,
    Associate Director, Lentivirus Process Development ,
    Johnson & Johnson


  • Jefferey Barlett Mr Jefferey Barlett,
    Senior Director Gene Therapy Strategic Development ,
    CSL Behring


  • Geoffrey Hodge Mr Geoffrey Hodge,
    Chief Technical Officer ,
    Unum Therapeutics


  • Richard Anderson Mr Richard Anderson,
    Senior Director, MSAT ,
    Fate Therapeutics Inc.


  • Mahendra Rao Mr Mahendra Rao,
    Chief Executive Officer ,
    panCella


  • Zhimei Du Mr Zhimei Du,
    Director Process Development & Operations ,
    Merck


  • Scott Burger Mr Scott Burger,
    Principal ,
    Advanced Cell & Gene Therapy LLC


Note: Product cover images may vary from those shown
5 of 5

From Therapeutics and Pharmaceuticals, Cell & Gene therapy-based companies:

Engineers/ Scientists/ Researchers/ Project leaders in:

  • Bioprocess development
  • Process development
  • GMP/Manufacturing
  • Cellular Therapy
  • Gene Therapy
  • Quality Control
  • Cell Engineering
  • Regulatory affairs
Note: Product cover images may vary from those shown
6 of 5

ADDRESS

Boston, MA
United States

Venue to be announced shortly.

Note: Product cover images may vary from those shown
Adroll
adroll